UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of report (Date of earliest event reported): February 22, 2008

 
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

 
Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
13-4087132
(IRS Employer Identification No.)

 
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
 
 
 
 
 
Item 2.02. Results of Operations and Financial Condition.

On February 22, 2008, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2007. Keryx also announced that on Monday, February 25, 2008, at 8:30am EST, Keryx will host an investor conference call during which Keryx will provide a brief financial overview of fourth quarter and year-end 2007 financial results and the business outlook for 2008. A copy of such press release is being furnished as Exhibit 99.1 to this report.
 
 
 
 
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
Keryx Biopharmaceuticals, Inc.
(Registrant)
   
Date: February 22, 2008  
 		  
 
By:   /s/ Michael S. Weiss
 
Michael S. Weiss
  Chairman and Chief Executive Officer
 


 
 
 
 

INDEX TO EXHIBITS


Exhibit
 
Number
Description
   
99.1
Press Release dated February 22, 2008.